Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine

Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from its PROMISE 1 Phase 3 clinical trial evaluating eptinezumab, Alder’s lead investigational product candidate for migraine prevention, in patients with episodic migraine.

As quoted in the press release:

“The significant increase in monthly migraine-free days demonstrate the potential relief that eptinezumab can deliver to migraine patients,” said Dr. Richard Lipton, Director of the Montefiore Headache Center, Albert Einstein College of Medicine. “Further, as demonstrated by the quality of life survey results, patients experienced improvements in areas such as bodily pain and physical function, illustrating the opportunity eptinezumab may provide to patients suffering from migraine.”

The observed safety profile for PROMISE 1, to date, is consistent with previously reported eptinezumab studies. The most commonly reported adverse events occurring at an incidence of 5 percent or greater across all eptinezumab treatment groups were upper respiratory infection (10.5 percent), nasopharyngitis (common cold) (6.8 percent) and sinusitis (3.6 percent).

Click here to read the full press release.